Redhill Biopharma Company Profile (NASDAQ:RDHL)

About Redhill Biopharma (NASDAQ:RDHL)

Redhill Biopharma logoRedhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RDHL
  • CUSIP: N/A
  • Web: www.redhillbio.com
Capitalization:
  • Market Cap: $155.33 million
  • Outstanding Shares: 17,163,000
Average Prices:
  • 50 Day Moving Avg: $8.65
  • 200 Day Moving Avg: $9.37
  • 52 Week Range: $8.16 - $15.27
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.53
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $583,000.00
  • Price / Sales: 266.42
  • Book Value: $2.84 per share
  • Price / Book: 3.19
Profitability:
  • EBIDTA: ($41,030,000.00)
  • Return on Equity: -70.00%
  • Return on Assets: -57.98%
Debt:
  • Current Ratio: 5.26%
  • Quick Ratio: 5.20%
Misc:
  • Average Volume: 65,733 shs.
  • Beta: 0.59
  • Short Ratio: 2.45
 

Frequently Asked Questions for Redhill Biopharma (NASDAQ:RDHL)

What is Redhill Biopharma's stock symbol?

Redhill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

How were Redhill Biopharma's earnings last quarter?

Redhill Biopharma Ltd. (NASDAQ:RDHL) announced its earnings results on Tuesday, July, 25th. The company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.02. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million. View Redhill Biopharma's Earnings History.

When will Redhill Biopharma make its next earnings announcement?

Redhill Biopharma is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Redhill Biopharma.

Where is Redhill Biopharma's stock going? Where will Redhill Biopharma's stock price be in 2017?

3 equities research analysts have issued 12 month target prices for Redhill Biopharma's shares. Their forecasts range from $25.00 to $33.00. On average, they expect Redhill Biopharma's share price to reach $28.33 in the next twelve months. View Analyst Ratings for Redhill Biopharma.

What are analysts saying about Redhill Biopharma stock?

Here are some recent quotes from research analysts about Redhill Biopharma stock:

  • 1. According to Zacks Investment Research, "Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). " (9/20/2017)
  • 2. FBR & Co analysts commented, "BeiGene presented updated data at ICML from BTK inhibitor BGB-3111’s clinical." (6/16/2017)

Who are some of Redhill Biopharma's key competitors?

Who are Redhill Biopharma's key executives?

Redhill Biopharma's management team includes the folowing people:

  • Dror Ben-Asher, Chairman of the Board, Chief Executive Officer
  • Micha Ben Chorin, Chief Financial Officer
  • Gilead Raday, Chief Operating Officer
  • Reza Fathi, Senior Vice President - Research & Development
  • Adi Frish, Senior Vice President - Business Development and Licensing
  • Uri Hananel Aharon, Chief Accounting Officer
  • Patricia Anderson, Vice President - Regulatory Affairs
  • Aida Bibliowicz, Vice President - Clinical Affairs Europe
  • Shani Maurice, Vice President - Business Development & Communications
  • Danielle T. Abramson Ph.D., Director - Intellectual Property & Research

Who owns Redhill Biopharma stock?

Redhill Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (2.45%), Migdal Insurance & Financial Holdings Ltd. (2.32%), Bank Hapoalim BM (1.02%), Candriam Luxembourg S.C.A. (0.42%), D.A. Davidson & CO. (0.26%) and Ingalls & Snyder LLC (0.24%). View Institutional Ownership Trends for Redhill Biopharma.

Who sold Redhill Biopharma stock? Who is selling Redhill Biopharma stock?

Redhill Biopharma's stock was sold by a variety of institutional investors in the last quarter, including Bank Hapoalim BM. View Insider Buying and Selling for Redhill Biopharma.

Who bought Redhill Biopharma stock? Who is buying Redhill Biopharma stock?

Redhill Biopharma's stock was bought by a variety of institutional investors in the last quarter, including Family Management Corp, D.A. Davidson & CO., Oppenheimer & Co. Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Redhill Biopharma.

How do I buy Redhill Biopharma stock?

Shares of Redhill Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Redhill Biopharma's stock price today?

One share of Redhill Biopharma stock can currently be purchased for approximately $9.05.


MarketBeat Community Rating for Redhill Biopharma (NASDAQ RDHL)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Redhill Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Redhill Biopharma (NASDAQ:RDHL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.33 (213.08% upside)

Analysts' Ratings History for Redhill Biopharma (NASDAQ:RDHL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/31/2017Roth CapitalSet Price TargetBuy$27.00HighView Rating Details
7/26/2017HC WainwrightSet Price TargetBuy$33.00HighView Rating Details
6/16/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/29/2016NomuraReiterated RatingBuyN/AView Rating Details
11/11/2015Ascendiant Capital MarketsLower Price TargetBuy$28.00 -> $26.00N/AView Rating Details
9/29/2015Northland SecuritiesInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Redhill Biopharma (NASDAQ:RDHL)
Earnings by Quarter for Redhill Biopharma (NASDAQ:RDHL)
Earnings History by Quarter for Redhill Biopharma (NASDAQ RDHL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017        
7/25/20176/30/2017($0.58)($0.60)$0.34 million$0.48 millionViewN/AView Earnings Details
5/3/20173/31/2017($0.64)($0.50)ViewN/AView Earnings Details
7/27/2016Q116($0.58)($0.06)ViewListenView Earnings Details
2/25/2016Q1($0.48)$0.04$0.05 millionViewListenView Earnings Details
11/9/2015Q315($0.51)($0.04)ViewN/AView Earnings Details
7/29/2015Q215($0.49)($0.07)ViewListenView Earnings Details
4/30/2015Q115($0.56)($0.50)ViewN/AView Earnings Details
2/26/2015Q414($0.60)$0.06ViewN/AView Earnings Details
11/10/2014($0.61)($0.50)ViewN/AView Earnings Details
7/24/2014($0.38)($0.52)ViewN/AView Earnings Details
6/6/2014($0.44)$0.39ViewN/AView Earnings Details
4/30/2014($0.44)$0.39$7.01 millionViewN/AView Earnings Details
11/12/2013Q3 13($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Redhill Biopharma (NASDAQ:RDHL)
2017 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.51)($0.51)($0.51)
Q3 20171($0.51)($0.51)($0.51)
Q4 20171$0.79$0.79$0.79
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Redhill Biopharma (NASDAQ:RDHL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Redhill Biopharma (NASDAQ:RDHL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Redhill Biopharma (NASDAQ:RDHL)
Latest Headlines for Redhill Biopharma (NASDAQ:RDHL)
Source:
DateHeadline
americanbankingnews.com logoContrasting Redhill Biopharma (RDHL) & AveXis (AVXS)
www.americanbankingnews.com - September 22 at 6:06 AM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - September 21 at 12:02 AM
streetinsider.com logoRedHill Biopharma (RDHL) Receives Notice of Allowance for New US Patent Covering its Combination Therapy for ... - StreetInsider.com
www.streetinsider.com - September 19 at 7:02 AM
finance.yahoo.com logoRedHill Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 19 at 7:02 AM
finance.yahoo.com logoRedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers
finance.yahoo.com - September 19 at 7:02 AM
finance.yahoo.com logoIs RedHill Biopharma Ltd (RDHL) Undervalued?
finance.yahoo.com - September 15 at 3:29 PM
seekingalpha.com logoRedhill (RDHL) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 1:40 AM
finance.yahoo.com logoRedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.
finance.yahoo.com - September 13 at 8:15 AM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Research Coverage Started at UBS AG
www.americanbankingnews.com - September 13 at 8:05 AM
americanbankingnews.com logo-$0.76 Earnings Per Share Expected for Redhill Biopharma Ltd. (RDHL) This Quarter
www.americanbankingnews.com - September 9 at 4:26 PM
globenewswire.com logoRedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference - GlobeNewswire (press release)
globenewswire.com - September 8 at 7:32 AM
nasdaq.com logoRedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference - Nasdaq
www.nasdaq.com - September 7 at 8:11 AM
finance.yahoo.com logoRedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference
finance.yahoo.com - September 7 at 8:11 AM
globenewswire.com logoRedHill Biopharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 1 at 7:55 AM
finance.yahoo.com logoRedHill Biopharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - August 31 at 9:15 AM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - August 29 at 8:40 AM
americanbankingnews.com logo$1.27 Million in Sales Expected for Redhill Biopharma Ltd. (RDHL) This Quarter
www.americanbankingnews.com - August 24 at 9:29 AM
streetinsider.com logoRedHill Biopharma (RDHL) Granted FDA Approval U.S. ... - StreetInsider.com
www.streetinsider.com - August 19 at 6:56 AM
finanznachrichten.de logoREDHILL BIOPHARMA LTD ADR
www.finanznachrichten.de - August 17 at 3:17 PM
finance.yahoo.com logoRedHill – keen on growth – makes another commercial play
finance.yahoo.com - August 17 at 3:17 PM
seekingalpha.com logoRedhill's Dilution Remedy, A Work In Process - Seeking Alpha
seekingalpha.com - August 17 at 7:17 AM
finance.yahoo.com logoRedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
finance.yahoo.com - August 17 at 7:17 AM
finanznachrichten.de logoRedHill Biopharma Ltd.: RedHill Biopharma Provides 2017 Semi-Annual Business Update
www.finanznachrichten.de - August 11 at 7:58 AM
americanbankingnews.com logo$1.27 Million in Sales Expected for Redhill Biopharma Ltd. (NASDAQ:RDHL) This Quarter
www.americanbankingnews.com - August 5 at 7:06 AM
americanbankingnews.com logoRedhill Biopharma Ltd. (NASDAQ:RDHL) Expected to Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - August 4 at 12:18 AM
streetinsider.com logoRedHill Biopharma (RDHL) Receives Positive DSMB ... - StreetInsider.com
www.streetinsider.com - August 1 at 5:28 AM
finance.yahoo.com logoRedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease
finance.yahoo.com - August 1 at 5:28 AM
americanbankingnews.com logoRedhill Biopharma Ltd. (NASDAQ:RDHL) Given a $27.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - July 31 at 3:32 PM
americanbankingnews.com logoZacks Investment Research Lowers Redhill Biopharma Ltd. (NASDAQ:RDHL) to Sell
www.americanbankingnews.com - July 29 at 8:36 AM
finance.yahoo.com logoRedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017
finance.yahoo.com - July 28 at 7:14 AM
americanbankingnews.com logoRedhill Biopharma Ltd. (NASDAQ:RDHL) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - July 26 at 4:31 PM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - July 26 at 11:44 AM
finance.yahoo.com logoRedHill Biopharma Reports 2017 Second Quarter Financial Results
finance.yahoo.com - July 26 at 6:43 AM
finance.yahoo.com logoRedHill Biopharma reports initial revenues in Q2 as it grows Raleigh ops
finance.yahoo.com - July 26 at 6:43 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: July 20, 2017
seekingalpha.com - July 21 at 6:35 AM
streetinsider.com logoRedHill Biopharma (RDHL) Reports Last Patient Visit in BEKINDA Phase II Study for IBS-D - StreetInsider.com
www.streetinsider.com - July 17 at 8:29 AM
finance.yahoo.com logoRedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D
finance.yahoo.com - July 17 at 8:29 AM
americanbankingnews.com logo$340,000.00 in Sales Expected for Redhill Biopharma Ltd. (RDHL) This Quarter
www.americanbankingnews.com - July 14 at 12:04 PM
streetinsider.com logoRedHill Biopharma (RDHL) Expects DSMB RHB-104 Phase III Study Meeting in Late July - StreetInsider.com
www.streetinsider.com - July 13 at 8:17 PM
finance.yahoo.com logoRedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease
finance.yahoo.com - July 13 at 8:35 AM
americanbankingnews.com logo Analysts Expect Redhill Biopharma Ltd. (RDHL) to Post -$0.58 EPS
www.americanbankingnews.com - July 12 at 4:16 PM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 9 at 7:52 PM
seekingalpha.com logoQ3 Biotech Catalyst Watch: Phase 3 Data Releases (Part 2) - Seeking Alpha
seekingalpha.com - July 6 at 4:39 PM
americanbankingnews.com logoRedhill Biopharma Ltd. (NASDAQ:RDHL) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - July 4 at 7:24 AM
finance.yahoo.com logoRedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis
finance.yahoo.com - June 19 at 10:07 AM
americanbankingnews.com logo-$0.58 EPS Expected for Redhill Biopharma Ltd. (RDHL) This Quarter
www.americanbankingnews.com - June 16 at 6:06 PM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - June 16 at 4:22 PM
streetinsider.com logoRedHill Biopharma (RDHL) Initiates Confirmatory Phase III Study with RHB-105 for H. pylori Infection
www.streetinsider.com - June 15 at 9:44 PM
streetinsider.com logoRedHill Biopharma (RDHL) Initiates Confirmatory Phase III Study ... - StreetInsider.com
www.streetinsider.com - June 15 at 4:43 PM
finance.yahoo.com logoRedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection
finance.yahoo.com - June 15 at 4:42 PM

Social

Chart

Redhill Biopharma (RDHL) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff